Savient’s mission is to develop and commercialize pharmaceutical specialty products. On September 14, 2010 the Food and Drug Administration (FDA) approved KRYSTEXXA® (pegloticase).
We have exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University and Mountain View Pharmaceuticals, Inc. Duke University developed the recombinant uricase enzyme and Mountain View developed the PEGylation technology used in the manufacture of KRYSTEXXA. Mountain View and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.
Currently, we sell and distribute branded and generic versions of Oxandrin® (oxandrolone). We launched our authorized generic version of oxandrolone in December 2006.
This site is intended for U.S. audiences only.